BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 35158765)

  • 1. Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.
    Marvin-Peek J; Savani BN; Olalekan OO; Dholaria B
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.
    Boucher JC; Shrestha B; Vishwasrao P; Leick M; Cervantes EV; Ghafoor T; Reid K; Spitler K; Yu B; Betts BC; Guevara-Patino JA; Maus MV; Davila ML
    Mol Ther Oncolytics; 2023 Dec; 31():100751. PubMed ID: 38075241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
    Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
    Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
    Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor T cells for acute myeloid leukemia.
    Fetsch V; Zeiser R
    Eur J Haematol; 2024 Jan; 112(1):28-35. PubMed ID: 37455578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations.
    Guijarro-Albaladejo B; Marrero-Cepeda C; Rodríguez-Arbolí E; Sierro-Martínez B; Pérez-Simón JA; García-Guerrero E
    Front Cell Dev Biol; 2024; 12():1376554. PubMed ID: 38694825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
    Atilla PA; McKenna MK; Watanabe N; Mamonkin M; Brenner MK; Atilla E
    Cytotherapy; 2022 Mar; 24(3):282-290. PubMed ID: 34955406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
    Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor T-cell therapy for T-ALL and AML.
    Wei W; Yang D; Chen X; Liang D; Zou L; Zhao X
    Front Oncol; 2022; 12():967754. PubMed ID: 36523990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia.
    Pasvolsky O; Daher M; Alatrash G; Marin D; Daver N; Ravandi F; Rezvani K; Shpall E; Kebriaei P
    Front Oncol; 2021; 11():800110. PubMed ID: 35083154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.
    Meyer JE; Loff S; Dietrich J; Spehr J; Jurado Jiménez G; von Bonin M; Ehninger G; Cartellieri M; Ehninger A
    Oncoimmunology; 2021; 10(1):1945804. PubMed ID: 34290907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.
    Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S
    Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Panorama of Immune Fighters Armored with CARs in Acute Myeloid Leukemia.
    Christodoulou I; Solomou EE
    Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37297016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
    Trad R; Warda W; Alcazer V; Neto da Rocha M; Berceanu A; Nicod C; Haderbache R; Roussel X; Desbrosses Y; Daguindau E; Renosi F; Roumier C; Bouquet L; Biichle S; Guiot M; Seffar E; Caillot D; Depil S; Robinet E; Salma Y; Deconinck E; Deschamps M; Ferrand C
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35803613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia.
    Wang X; Zhang Y; Xue S
    Ann Hematol; 2024 Jun; 103(6):1843-1857. PubMed ID: 38381173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
    Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond.
    Epperly R; Gottschalk S; Velasquez MP
    Children (Basel); 2020 Feb; 7(2):. PubMed ID: 32079207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
    Mardiros A; Dos Santos C; McDonald T; Brown CE; Wang X; Budde LE; Hoffman L; Aguilar B; Chang WC; Bretzlaff W; Chang B; Jonnalagadda M; Starr R; Ostberg JR; Jensen MC; Bhatia R; Forman SJ
    Blood; 2013 Oct; 122(18):3138-48. PubMed ID: 24030378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
    Morgan MA; Kloos A; Lenz D; Kattre N; Nowak J; Bentele M; Keisker M; Dahlke J; Zimmermann K; Sauer M; Heuser M; Schambach A
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.